Welcome to our dedicated page for KIN news (Ticker: KIN), a resource for investors and traders seeking the latest updates and insights on KIN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect KIN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of KIN's position in the market.
Kindred Biosciences (NASDAQ: KIN) will present at two key healthcare conferences: the Barclays Global Healthcare Conference on March 10, 2021, and the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. Dr. Richard Chin, CEO, will be available for one-on-one meetings to discuss recent developments and study results of their therapeutic programs. Presentations will be available via webcast, with recordings accessible for 30 days afterward. Kindred Biosciences focuses on developing innovative biologics aimed at improving pet health.
Kindred Biosciences, Inc. (NASDAQ: KIN) announced its submission of efficacy data for the monoclonal antibody KIND-030 to the USDA for review, targeting canine parvovirus. This marks a significant step towards obtaining approval for its prophylactic indication. CEO Richard Chin emphasized the importance of this data in transforming how parvovirus is treated. However, the company warns of regulatory risks and potential delays due to COVID-19. The completion of clinical studies is now expected in Q2 2021, though it doesn't affect the agreement with Elanco Animal Health.
Kindred Biosciences (NASDAQ: KIN), a biopharmaceutical company dedicated to improving pet health, will present at the BofA Securities Animal Health Virtual Summit on February 25. CEO Dr. Richard Chin will deliver a presentation via webcast at 10:50 AM ET, followed by virtual one-on-one meetings with investors. The company aims to develop safe, effective biologics for pets based on successful human therapeutics. An archived version of the webcast will be available for 30 days on the KindredBio website.
Kindred Biosciences (NASDAQ: KIN) has appointed Lyndon Lien, Ph.D., and Nanxi Liu to its Board of Directors, effective February 5, 2021. CEO Richard Chin expressed enthusiasm for their extensive experience in biotech and entrepreneurship, which is expected to bring valuable insights to KindredBio's mission of developing innovative biologics for pets. Additionally, Dr. Ernest Mario will retire from the board but remain an advisor for the year. KindredBio focuses on creating safe and effective treatments for pets based on validated human therapeutics.
Kindred Biosciences, Inc. (NASDAQ: KIN) announced the initiation of a pivotal efficacy study for tirnovetmab, a monoclonal antibody targeting interleukin (IL)-31 to treat atopic dermatitis in dogs. Affects 10-15% of dogs globally, with a market size nearing $900 million. CEO Richard Chin emphasized a strong demand for new biologics, citing over 70% of veterinarians seeking alternatives. The study marks a significant milestone for KindredBio and aligns with their strategy to develop innovative therapies for pets.
Kindred Biosciences (NASDAQ: KIN) reported positive results from a pilot study assessing its anti-TNFα antibody for treating canine inflammatory bowel disease (IBD). Conducted with 10 dogs, the randomized, placebo-controlled trial found that 75% of treated dogs achieved significant remission compared to only 17% in the placebo group. The treatment demonstrated early and lasting effects, indicating strong potential for this therapeutic in addressing IBD, a common condition in dogs. CEO Richard Chin emphasized the unmet need in canine gastrointestinal diseases and the promising outcomes of the study.
Kindred Biosciences, Inc. (NASDAQ: KIN) announced a partnership granting Elanco Animal Health exclusive global rights to its monoclonal antibody, KIND-030, targeting canine parvovirus (CPV). KindredBio will receive an upfront payment of $500,000 and potential milestone payments totaling $16 million for development and $94 million in sales milestones. Currently, there are no approved treatments for CPV, which affects about 250,000 dogs annually in the U.S. This collaboration aims to enhance market access for KIND-030.
Kindred Biosciences (NASDAQ: KIN) is set to present at the Guggenheim Animal Health Summit on December 7, 2020, at 10am ET. CEO Dr. Richard Chin will join the panel discussing how biologics will transform veterinary practices. Additionally, he will hold one-on-one meetings with investors to discuss recent developments and key therapeutic programs. Kindred Biosciences focuses on developing biologics that improve pets' lives, leveraging validated human medicine targets for safe and effective treatments.
Kindred Biosciences (NASDAQ: KIN) will present at the Stifel Virtual Healthcare Conference on November 17 and participate in the A.G.P. Virtual Healthcare Symposium on November 19. CEO Dr. Richard Chin will hold one-on-one meetings to discuss recent developments and study results from key therapeutic programs. The Stifel conference presentation is scheduled from 2:40–3:10 PM ET. Archived webcasts will be available for 30 days. KindredBio is committed to developing safe and effective therapeutics for pets.
Kindred Biosciences (NASDAQ: KIN) reported Q3 2020 net revenues of $1.0 million and a net loss of $12.2 million ($0.31 per share). Positive outcomes from its pivotal efficacy study for canine parvovirus (KIND-030) were highlighted, with dogs treated showing no infection. The company anticipates completion of pivotal studies and product approvals by early 2021. Despite project advancements, they experienced a revenue decline related to Mirataz sales due to a transition to Dechra branding. Total cash available as of September 30, 2020, was $66.8 million, down from $73.5 million at year-end 2019.
